Flagship refocuses stealth RNA biotech; Mesoblast enacts pay cuts for executives

Ra­di­al Ther­a­peu­tics, a stealth-stage start­up in­side the biotech in­cu­ba­tor Flag­ship Pi­o­neer­ing, is re­fo­cus­ing.

“Un­for­tu­nate­ly, we found out re­cent­ly that Ra­di­al has de­cid­ed to stop pur­su­ing the goal of drug­ging RNA with small mol­e­cules, ef­fec­tive­ly end­ing the com­pa­ny,” an em­ploy­ee post­ed to LinkedIn ear­li­er this month. “While Flag­ship is try­ing to place every­one in­to oth­er po­si­tions in their ecosys­tem, it isn’t a guar­an­tee.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.